Follow on Google News News By Tag * Antibacterial Drug Market Analysis * Antibacterial Drugs * Antibacterial Healthcare Products * Antibacterial Research Analy * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News |  The Antibacterial Drug Market: Analysis 2008-2013Visiongain is proud to announce the release of the brand new report "The Antibacterial Drug Market". The antibacterial market is large in terms of disease area as well as the different drug classes used to treat these infections.
By: Visiongain Ltd. This brand new market analysis by visiongain examines the prospects for antibacterial drugs from 2008-2013, including sales forecasts for leading pharmaceutical products. The antibacterial market is large in terms of disease area as well as the different drug classes used to treat these infections. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. In the light of this, including other factors, visiongain predicts this market to decline in revenues – but which products will suffer most? How can you fight this generic competition? The antibacterial market only contained one blockbuster drug in 2006, this being Johnson & Johnson’s Levaquin. Visiongain predicts that there will be room for one more blockbuster drug as Levaquin will lose patent protection. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints. This report will specifically analyse the world markets for the following classes of antibacterials: • Cephalosporins • Macrolides • Penicillins • Fluoroquinolones • Carbapenems • Miscellaneous. The group 'miscellaneous' is an assorted group of antibacterials which includes the minor classes: the tetracyclines, aminoglycosides, glycopeptides and sulphonamides plus individual antibacterials such as Zyvox and Vancocin. The Antibacterial Drug Market Analysis 2008 examines the market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion. In particular, The Antibacterial Drug Market concentrates on the following essential aspects of the market: • Discussion of the current pharmaceutical market • Forecast of the worldwide pharmaceutical market from 2008-2013 • Drivers and restraints facing the antibacterial drug market • Opportunities and threats facing the antibacterial drug market • Growth of the antibacterial drugs market between 2008-2013 • Commercial prospects for the market-leading drugs, with sales forecasts from 2008-2013 • Individual forecasts of the leading drug classes from 2008-2013 • The potential of generics manufacturers to penetrate this market • Pipeline developments with blockbuster potential • Currently marketed drugs with blockbuster potential • Discussion of unmet therapeutic needs and relative advantages of products Why you should buy this report: • To receive a comprehensive analysis of the prospects for antibacterial drugs from 2008-2013 • To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2008-2013 • To determine key activities of leading companies • To discover “hot” pipeline developments and up-and-coming products • To determine the forces that influence the market for antibacterial drugs: • Competitive characteristics of the market • Drivers • Restraints • Strengths, weaknesses, opportunities and threats (SWOT analysis) • To find out where the market is heading - both technologically and commercially Companies Listed Abbott Agennix Arpida Asubio Pharma Basilea Bausch & Lomb Daiichi Sankyo Eli Lilly Enanta Flamel Technologies Genaera Genzyme Giaconda Gilead Sciences GSK Inhibitex InSite Vision Johnson & Johnson Leiden University Merck&Co MiddleBrook Migenix Neosil NovaBay Novartis Novexel Optimer Ortho-McNeil Otsuka Pathogenics Pfizer Pharming Photopharmica Procter & Gamble Rib-X Roche Schering-Plough Shogoo Pharmaceuticals Takeda Targanta Tekmira ; Aradigm Theravance Wakunaga Wockhardt Wyeth XOMA Visiongain ltd. 4th Floor, BSG House, 226 236 City Road, London EC1V 2QY United Kingdom Telephone: +44 (0) 20 7336 6100 Fax: +44 (0) 20 7549 9930 info@visiongainglobal.com Or Visit at: http://www.visiongain.com/ Or http://www.visiongain.com # # # Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services. End
| ||||||||||||||||||||||||||||||||||||||||||||
